Curis Lifesciences Ltd
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
- Market Cap ₹ 88.9 Cr.
- Current Price ₹ 110
- High / Low ₹ 148 / 83.6
- Stock P/E 12.8
- Book Value ₹ 58.6
- Dividend Yield 0.00 %
- ROCE 21.2 %
- ROE 21.8 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 39.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Working capital days have increased from 123 days to 232 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 23.70 | 35.21 | 35.13 | 49.13 | 60.63 | |
| 20.12 | 31.95 | 26.74 | 39.59 | 49.50 | |
| Operating Profit | 3.58 | 3.26 | 8.39 | 9.54 | 11.13 |
| OPM % | 15.11% | 9.26% | 23.88% | 19.42% | 18.36% |
| 0.02 | 0.34 | 0.31 | 0.51 | 0.27 | |
| Interest | 1.62 | 1.33 | 0.85 | 1.11 | 1.14 |
| Depreciation | 0.75 | 0.73 | 0.68 | 0.67 | 0.70 |
| Profit before tax | 1.23 | 1.54 | 7.17 | 8.27 | 9.56 |
| Tax % | 59.35% | 20.13% | 32.22% | 26.24% | 27.62% |
| 0.49 | 1.23 | 4.87 | 6.11 | 6.92 | |
| EPS in Rs | 9.80 | 24.60 | 97.40 | 10.30 | 8.56 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 78% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 39% |
| Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 | 5.93 | 8.08 |
| Reserves | -1.40 | -0.18 | 5.37 | 10.29 | 39.27 |
| 17.62 | 16.19 | 17.09 | 15.61 | 21.59 | |
| 10.68 | 13.16 | 10.91 | 10.70 | 12.58 | |
| Total Liabilities | 27.40 | 29.67 | 33.87 | 42.53 | 81.52 |
| 12.33 | 12.20 | 11.59 | 10.99 | 10.77 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.02 | 1.33 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 15.06 | 17.46 | 22.27 | 31.51 | 69.41 | |
| Total Assets | 27.40 | 29.67 | 33.87 | 42.53 | 81.52 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 4.95 | 3.35 | 0.28 | -1.76 | -16.42 | |
| -0.37 | -0.55 | -0.06 | -0.02 | -1.59 | |
| -4.58 | -2.76 | 0.05 | 1.67 | 20.87 | |
| Net Cash Flow | -0.01 | 0.04 | 0.27 | -0.11 | 2.86 |
| Free Cash Flow | 4.56 | 2.77 | 0.21 | -1.85 | -18.22 |
| CFO/OP | 138% | 103% | 3% | -2% | -127% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 96.10 | 98.17 | 104.94 | 55.87 | 67.55 |
| Inventory Days | 208.46 | 114.92 | 273.22 | 347.26 | 297.00 |
| Days Payable | 359.58 | 262.67 | 210.40 | 112.29 | 71.22 |
| Cash Conversion Cycle | -55.01 | -49.58 | 167.75 | 290.83 | 293.32 |
| Working Capital Days | -16.02 | -20.84 | 36.26 | 99.63 | 232.20 |
| ROCE % | 17.21% | 40.64% | 34.24% | 21.25% |
Insights
In beta| Mar 2023 | Mar 2024 | Jan 2026 | |
|---|---|---|---|
| EBITDA Margin % |
|
||
| PAT Margin % |
|||
| Export Ready Products (New Registrations) Number |
|||
| Domestic Turnover Share % |
|||
| Export Turnover Share % |
|||
| Land Size Square Meters |
|||
| Number of Developed Formulations (Portfolio) Number |
|||
| Own Brand Export Share in Revenue % |
|||
| Total Construction Area (Manufacturing Facility) Square Meters |
|||
Extracted by Screener AI
Documents
Announcements
-
Disclosure under SEBI Takeover Regulations
2 June 2026 - Curis Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
-
Outcome of Board Meeting
30 May 2026 - Board approved FY26 audited standalone results; profit rose to ₹691.63 lakh, with planned 51% Uninova investment.
-
Statement of deviation(s) or variation(s) under Reg. 32
30 May 2026 - Curis filed FY26 IPO proceeds utilization statement for ₹27.52 crore; no deviation reported.
-
Integrated Filing- Financial
30 May 2026 - Board approved FY26 audited results and 51% acquisition of Uninova Lifesciences, with Rs 20.655 lakh paid.
-
Structural Digital Database
30 May 2026 - Submitted SDD compliance certificate for year ended 31 March 2026; no non-compliances reported.
Annual reports
No data available.
Concalls
-
Mar 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptPPT
-
Jan 2026TranscriptPPT
Business Profile[1]
Curis Lifesciences is a pharmaceutical company engaged in the production of a wide range of formulations across tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.